CBRI yields 2000000.00% · ABBV yields 3.12%● Live data
📍 CBRI pulled ahead of the other in Year 1
Combined, CBRI + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CBRI + ABBV for your $10,000?
CMTSU Liquidation, Inc. operates as an information technology (IT) service company worldwide. It operates as an independent software vendor or channel partner; and provides project management, application and technical consulting, and database administration for implementation projects and managed-services. The company also offers managed services; and enterprise application, IT strategy, and business process consultancy services, as well as project planning, systems implementation and integration, training and change management, and application management. Its application development and management/staffing services provide analysis, design, development, testing and quality assurance, implementation, and maintenance of its client's business applications. In addition, the company offers staffing services covering software development lifecycle, as well as steady-state operations; and sells various IT hardware and software products. It serves Global 2000 blue-chip companies in industries, such as manufacturing, retail, education, healthcare and life sciences, energy and utilities, financial services, and the public sector. The company was formerly known as Ciber, Inc. and changed its name to CMTSU Liquidation, Inc. in June 2017. CMTSU Liquidation, Inc. was founded in 1974 and is based in Denver, Colorado. On April 9, 2017, CMTSU Liquidation, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on December 20, 2018.
Full CBRI Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.